Previous Close | 9.59 |
Open | 9.67 |
Bid | 9.89 x 900 |
Ask | 9.92 x 200 |
Day's Range | 9.61 - 10.02 |
52 Week Range | 1.76 - 15.40 |
Volume | |
Avg. Volume | 5,173,208 |
Market Cap | 1.139B |
Beta (5Y Monthly) | 1.15 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.78 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.00 |
WESTLAKE VILLAGE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024. Details for the company’s participation are as follows: Fireside Chat Date: Thursday, April 11, 2024 Fireside Chat Time: 2:15 pm EDT T
Arcutis Biotherapeutics, Inc. (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.